537 related articles for article (PubMed ID: 36420910)
1. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
[TBL] [Abstract][Full Text] [Related]
2. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
3. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
[TBL] [Abstract][Full Text] [Related]
4. Can 11C-PiB-PET Relative Delivery R1 or 11C-PiB-PET Perfusion Replace 18F-FDG-PET in the Assessment of Brain Neurodegeneration?
Oliveira FPM; Moreira AP; de Mendonça A; Verdelho A; Xavier C; Barroca D; Rio J; Cardoso E; Cruz Â; Abrunhosa A; Castelo-Branco M
J Alzheimers Dis; 2018; 65(1):89-97. PubMed ID: 30056421
[TBL] [Abstract][Full Text] [Related]
5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
6. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
7. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies.
Peretti DE; Vállez García D; Reesink FE; van der Goot T; De Deyn PP; de Jong BM; Dierckx RAJO; Boellaard R
PLoS One; 2019; 14(1):e0211000. PubMed ID: 30653612
[TBL] [Abstract][Full Text] [Related]
8. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
10. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
[TBL] [Abstract][Full Text] [Related]
11. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
[TBL] [Abstract][Full Text] [Related]
12. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
[TBL] [Abstract][Full Text] [Related]
13. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
14. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
[TBL] [Abstract][Full Text] [Related]
15. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
16. Comparability of [
Rodriguez-Vieitez E; Leuzy A; Chiotis K; Saint-Aubert L; Wall A; Nordberg A
J Cereb Blood Flow Metab; 2017 Feb; 37(2):740-749. PubMed ID: 27107028
[TBL] [Abstract][Full Text] [Related]
17. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
Grimmer T; Riemenschneider M; Förstl H; Henriksen G; Klunk WE; Mathis CA; Shiga T; Wester HJ; Kurz A; Drzezga A
Biol Psychiatry; 2009 Jun; 65(11):927-34. PubMed ID: 19268916
[TBL] [Abstract][Full Text] [Related]
18. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
[TBL] [Abstract][Full Text] [Related]
19. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
20. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD
Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]